Economic burden of common variable immunodeficiency: annual cost of disease

References

• Cunningham-Rundles C, Ponda PP. Molecular defects in T- and B-cell primary immunodeficiency diseases. Nat Rev Immunol 2005;5(11):880-92
   PubMed Web of Science ®Google Scholar
• Latif AH, Tabassomi F, Abolhassani H, et al. Molecular diagnosis of primary immunodeficiency diseases in a developing country: Iran as an example. Expert Rev Clin Immunol 2014;10(3):385-96
   PubMed Web of Science ®Google Scholar
• Seymour B, Miles J, Haeney M. Primary antibody deficiency and diagnostic delay. J Clin Pathol 2005;58(5):546-7
   PubMed Web of Science ®Google Scholar
• Shearer WT, Cunningham-Rundles C, Ochs HD. Primary immunodeficiency: looking backwards, looking forwards. J Allergy Clin Immunol 2004;113(4):607-9
   PubMed Web of Science ®Google Scholar
• Ochs HD, Hitzig WH. History of primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol 2012;12(6):577-87
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Mohammadinejad P, Abolhassani H, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol 2014;34(4):478-90
   PubMed Web of Science ®Google Scholar
• Rezaei N, Aghamohammadi A, Moin M, et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry. J Clin Immunol 2006;26(6):519-32
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Abolhassani H, Latif A, et al. Long-term evaluation of a historical cohort of Iranian common variable immunodeficiency patients. Expert Rev Clin Immunol 2014;10(10):1405-17
   PubMed Web of Science ®Google Scholar
• Abolhassani H, Aghamohammadi A, Abolhassani F, et al. Health policy for common variable immunodeficiency: burden of the disease. J Investig Allergol Clin Immunol 2011;21(6):454-8
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Moein M, Farhoudi A, et al. Primary immunodeficiency in Iran: first report of the National Registry of PID in Children and Adults. J Clin Immunol 2002;22(6):375-80
   PubMed Web of Science ®Google Scholar
• Ewert T. Instrumentality of the International Classification of Functioning, Disability and Health (ICF) in classification of long-term consequences of diseases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012;55(4):459-67
   PubMed Web of Science ®Google Scholar
• Chapel H. Classification of primary immunodeficiency diseases by the International Union of Immunological Societies (IUIS) Expert Committee on Primary Immunodeficiency 2011. Clin Exp Immunol 2012;168(1):58-9
   PubMed Web of Science ®Google Scholar
• The international classification of diseases, 10th Edition (ICD-10) changeover is coming. Optometry 2010;81(10):551-3
   PubMedGoogle Scholar
• Aghamohammadi A, Farhoudi A, Moin M, et al. Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin Diagn Lab Immunol 2005;12(7):825-32
   PubMedGoogle Scholar
• Aghamohammadi A, Pouladi N, Parvaneh N, et al. Mortality and morbidity in common variable immunodeficiency. J Trop Pediatr 2007;53(1):32-8
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Montazeri A, Abolhassani H, et al. Health-related quality of life in primary antibody deficiency. Iran J Allergy Asthma Immunol 2011;10(1):47-51
   PubMed Web of Science ®Google Scholar
• Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002;20(7):455-62
   PubMed Web of Science ®Google Scholar
• Brazier J, Deverill M. A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Health Econ 1999;8(1):41-51
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Abolhassani H, Moazzami K, et al. Correlation between common variable immunodeficiency clinical phenotypes and parental consanguinity in children and adults. J Investig Allergol Clin Immunol 2010;20(5):372-9
   PubMed Web of Science ®Google Scholar
• Helbert M. Primary immunodeficiencies: An Introduction for Managers. UKPIN executive summary. 2010. Available from: http://www.ukpin.org.uk/home/reports/Managers.pdf. p. 1-4
   Google Scholar
• Modell V, Gee B, Lewis DB, et al. Global study of primary immunodeficiency diseases (PI)–diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res 2011;51(1):61-70
   PubMed Web of Science ®Google Scholar
• Foundation JM. Economic impact study: comparing undiagnosed and diagnosed patients with primary immunodeficiencies. 2010
   Google Scholar
• Boyle M, Scalchunes C. Impact of intravenous immunoglobulin (IVIG) treatment among patients with Primary Immunodeficiency diseases. Pharmaceuticals Policy and Law 2008;10:133-46
   Google Scholar
• Bonnet P. Undiagnosed primary immunodeficiency disorders are associated with substantial healthcare cost and resource use. Baxter International Inc 2008. Available from: http://www.baxter.com.sg/press_room/press_releases/2008/03-15-08-burden_of_illness.html
   Google Scholar
• Membe SK, Ho C, Cimon K, et al. Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol Allergy Clin North Am 2008;28(4):861-74
   PubMed Web of Science ®Google Scholar
• Haddad L, Perrinet M, Parent D, et al. [Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution]. Rev Med Interne 2006;27(12):924-6
   PubMed Web of Science ®Google Scholar
• Darba J, Restovic G, Kaskens L, et al. Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain. J Clin Pharmacol 2012;52(4):566-75
   PubMed Web of Science ®Google Scholar
• Simoens S. Treatment of primary immunodeficiency with Kiovig: a literature review. Adv Ther 2010;27(3):142-9
   PubMed Web of Science ®Google Scholar
• Galli E, Barbieri C, Cantani A, et al. Treatment with gammaglobulin preparation for intravenous use in children with humoral immunodeficiency: clinical and immunologic follow-up. Ann Allergy 1990;64(2 Pt 1):147-50
   PubMedGoogle Scholar
• Beaute J, Levy P, Millet V, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol 2010;160(2):240-5
   PubMed Web of Science ®Google Scholar
• Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995;345(8946):365-9
   PubMed Web of Science ®Google Scholar
• Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ 2005;6(1):24-9
   PubMedGoogle Scholar
• Liu Z, Albon E, Hyde C. The effectiveness and cost effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation. West Midlands Health Technology Assessment Collaboration Department of Public Health and Epidemiology The University of Birmingham 2006;54:1-168
   Google Scholar
• Ho C, Membe S, Cimon K, et al. Subcutaneous versus intravenous immunoglobulin for primary immunodeficiencies: systematic review and economic evaluation. Technology report number 98]. Ottawa: Canadian Agency for Drugs and Technologies in Health 2008. Available from: http://www.uhhospitals.org/rainbow/services/allergy-immunology/~/media/uh/documents/services/rainbow-466_immunoglobulin-primary-immunodefiencies_to_e.ashx. p 1-8
   Google Scholar
• Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol 2012;32(6):1180-92
   PubMed Web of Science ®Google Scholar
• Rezaei N, Abolhassani H, Aghamohammadi A, et al. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol 2011;7(3):301-16
   PubMed Web of Science ®Google Scholar